ARMP
AMEX · Biotechnology
Armata Pharmaceuticals Inc
$8.37
-0.98 (-10.48%)
Financial Highlights (FY 2026)
Revenue
5.93M
Net Income
-21,688,870
Gross Margin
—
Profit Margin
-365.6%
Rev Growth
+5.0%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 64.0% | 64.0% |
| Operating Margin | -778.3% | -700.5% | -25.7% | -26.9% |
| Profit Margin | -365.6% | -347.3% | -31.4% | -24.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 5.93M | 5.65M | 51.72M | 48.38M |
| Gross Profit | — | — | 33.09M | 30.96M |
| Operating Income | -46,178,992 | -39,581,993 | -13,268,820 | -13,017,580 |
| Net Income | -21,688,870 | -18,590,460 | -16,237,176 | -12,069,043 |
| Gross Margin | — | — | 64.0% | 64.0% |
| Operating Margin | -778.3% | -700.5% | -25.7% | -26.9% |
| Profit Margin | -365.6% | -347.3% | -31.4% | -24.9% |
| Rev Growth | +5.0% | +5.0% | -2.8% | -3.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 107.00M | 137.33M |
| Total Equity | — | — | 94.95M | 97.16M |
| D/E Ratio | — | — | 1.13 | 1.41 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -44,654,777 | -40,401,941 | -19,844,642 | -21,697,061 |
| Free Cash Flow | — | — | -12,228,215 | -11,985,347 |